ICC panel rules in cancer treatment dispute
An Austrian pharmaceuticals company has reportedly prevailed in a €2 billion ICC dispute with a Taiwanese partner that sought to end their agreement to develop and market a blood cancer drug.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.